Comparison of Computerized Prescription Support Systems in COVID-19 Patients: INTERCheck and Drug-PIN

Martocchia, Antonio; Bruscia, Clara; Conforti, Giulia; Falangone, Francesca; Marini, Valentina; Pennica, Alfredo; Pezzuto, Aldo; March, Massimiliano Rocchietti; Sentimentale, Alberto; Spuntarelli, Valerio; Tafaro, Laura; Rícci, Alberto; Simmaco, Maurizio; Sesti, Giorgio; Preißner, Robert; Martelletti, Paolo

doi:10.1007/s42399-021-01079-9

Cited by 2 publications

(1 citation statement)

References 29 publications

(22 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…24 The risk associated with the different drugs is calculated by the software not only on the basis of the pharmacodynamic properties but also taking into account certain patient characteristics, such as sex, age, weight, lifestyle habits (coffee, alcohol, nicotine consumption), liver and kidney function, pharmacogenetic profile and concomitant therapies. 25 The ranking is thus based on the likelihood of a drug having adverse effects in the overall context of multimorbid and polytreated patients (which is the population most susceptible to drug-related adverse events). 26 In this way, an attempt is made to study the reality of the situation in which drugs give adverse events and to identify those that give them most often.…”

Section: Dovepressmentioning

confidence: 99%

Prescription Advice Based on Data of Drug-Drug-Gene Interaction of Patients with Polypharmacy

Salamone¹,

Spirito²,

Simmaco³

et al. 2022

PGPM

Self Cite

View full text Add to dashboard Cite

Purpose Pharmacogenetic counselling is a complex task and requires the efforts of an interdisciplinary team, which cannot be implemented in most cases. Therefore, simple rules could help to minimize the risk of medications incompatible with each other or with frequent genetic variants. Patients and Methods One hundred and eighty-four multi-morbid Caucasian patients suffering from side effects or inefficient therapy were enrolled and genotyped. Their medication was analyzed by a team of specialists using Drug-PIN ® (medication support system) and individual recommendations for 34 drug classes were generated. Results In each of the critical drug classes, 50% of the drugs cannot be recommended to be prescribed in typical drug cocktails. PPIs and SSRI/SNRIs represent the most critical drug classes without showing a single favorable drug. Among the well-tolerated drugs (not recommended for less than 5% of the patients) are metamizole, celecoxib, olmesartan and famotidine. For each drug class, a ranking of active ingredients according to their suitability is presented. Conclusion Genotyping and its profound analysis are not available in many settings today. The consideration of frequent alterations of metabolic elimination routes and drug–drug–gene interactions by using simple rankings can help to avoid many incompatibilities, side effects and inefficient therapies.

show abstract

Section: Dovepressmentioning

confidence: 99%

Prescription Advice Based on Data of Drug-Drug-Gene Interaction of Patients with Polypharmacy

Salamone¹,

Spirito²,

Simmaco³

et al. 2022

PGPM

Self Cite

View full text Add to dashboard Cite

show abstract

Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY study

Scagnoli,

Pisegna,

Toss

et al. 2024

npj Breast Cancer

View full text Add to dashboard Cite

Abemaciclib demonstrated clinical benefit in women affected by HR+/HER2− advanced breast cancer (aBC). Drug-drug interactions (DDIs) can lead to reduced treatment efficacy or increased toxicity. This retro-prospective study aimed to evaluate outcomes, DDIs’ impact, and toxicities of abemaciclib combined with endocrine therapy in a real-world setting. Patients from 12 referral Italian hospitals with HR+/HER2− aBC who received abemaciclib were included. Clinical data about comorbidities, concurrent medications, outcomes, and adverse events (AE) were collected. Drug-PIN® (Personalized Interactions Network) is a tool recognizing the role of multiple interactions between active and/or pro-drug forms combined with biochemical and demographic patient data. The software was used to define the Drug-PIN score and Drug-PIN tier (green, yellow, dark yellow, and red) for each patient. Univariate and multivariate analyses were performed to identify predictors of patients’ PFS or toxicity. One hundred seventy-three patients were included. 13% of patients had >75years. The overall response rate (ORR) was 63%. The general population’s median PFS (mPFS) was 22 months (mo), while mOS were not reached. Patients treated with abemaciclib in combination with AI and fulvestrant had a mPFS of 36 and 19 mo, respectively. The most common toxicities were diarrhea, asthenia, and neutropenia detected in 63%,49%, and 49% of patients. The number of concomitant medications and comorbidities were not associated with survival outcomes (22 vs 17 mo, p = 0.068, p = 0.99). Drug-PIN tier from dark yellow to red and Drug-PIN score >12 were associated with shorter PFS compared to no/low-risk DDIs and score <12 (15 vs 23, p = 0.005, p = 0.0017). Drug interaction was confirmed as an independent biomarker in a multivariate model (p = 0.02). No difference in any grade AE, severe toxicities, and diarrhea were detected among different age subgroups. No association was found between Drug-PIN score or Drug-PIN tier and overall toxicity (p = 0.44), severe AEs (p = 0.11), or drug reduction (p = 0.27). The efficacy and safety of abemaciclib plus ET were confirmed in a real-world setting, even in the elderly population and patients with comorbidities. Evaluation of DDIs with Drug-PIN appears to be an independent predictor of PFS.

show abstract

Comparison of Computerized Prescription Support Systems in COVID-19 Patients: INTERCheck and Drug-PIN

Cited by 2 publications

References 29 publications

Prescription Advice Based on Data of Drug-Drug-Gene Interaction of Patients with Polypharmacy

Prescription Advice Based on Data of Drug-Drug-Gene Interaction of Patients with Polypharmacy

Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY study

Contact Info

Product

Resources

About